Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer  

作　　者：Xue-Mei Yi Hong-Qiao Cai Yan Jiao 

机构地区：[1]Department of Second Operation Room,The First Hospital of Jilin University,Changchun 130021,Jilin Province,China [2]Department of Hepatobiliary and Pancreatic Surgery,General Surgery Center,The First Hospital of Jilin University,Changchun 130021,Jilin Province,China

出　　处：《World Journal of Gastrointestinal Surgery》2025年第2期16-19,共4页世界胃肠外科杂志(英文)

基　　金：Supported by Jilin Provincial Natural Science Foundation,No.YDZJ202401650ZYTS。

摘　　要：This editorial discusses Christodoulidis et al's article,which appeared in the most recent edition.The clinical trials have demonstrated the programmed cell death receptor 1(PD-1)inhibitor Pembrolizumab involved combination therapy can improve the efficacy of advanced gastric cancer(AGC).Pembrolizumab combined with chemotherapy can enhance its sensitivity,and further eliminate tumor cells that develop resistance to chemotherapy.The combination of Pembrolizumab and Trastuzumab targeting human epidermal growth factor receptor 2 showed improved prognosis.The overall toxic effects of Pembrolizumab are significantly lower than traditional chemotherapy,and the safety is controllable.PD-1 inhibitor Pembrolizumab sheds a light on the treatment of AGC and brings new hope to the clinical practice.

关 键 词：Programmed cell death receptor 1 inhibitor Pembrolizumab Advanced gastric cancer CHEMOTHERAPY TRASTUZUMAB 

分 类 号：R735.2[医药卫生—肿瘤]